Cutaneous dalteparin reactions associated with antibodies of heparin-induced thrombocytopenia

Annals of Pharmacotherapy

Volumn 37, Issue 5, 2003, Pages 655-658

  Payne, Sonja M ^a   Kovacs, Michael J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Dalteparin; Heparin induced thrombocytopenia

Indexed keywords

ALLOPURINOL; ANTIBODY; ANTINEOPLASTIC AGENT; CARMUSTINE; DALTEPARIN; DEXAMETHASONE; HEMOGLOBIN; HEPARIN; LEVOFLOXACIN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; METRONIDAZOLE; PENICILLIN DERIVATIVE; SULFANILAMIDE DERIVATIVE; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; DOPPLER ECHOGRAPHY; DRUG HYPERSENSITIVITY; ENZYME IMMUNOASSAY; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HUMAN; MALE; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0037406305     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C327     Document Type: Article

References (18)

1. Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost 1997;78:1422-5.
2. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-98.
3. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Waleng JM. Low molecular weight heparins: a developmental perspective. Exp Opin Invest Drugs 1997;6:705-33.
4. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
5. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
6. White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: including six cases of heparin-induced skin necrosis. Ann Surg 1978;190:595-608.
7. Ojeda E, Perez MC, Mataix R, Arbelo A, Jimenez S, Campo C, et al. Skin necrosis with a low molecular weight heparin. Br J Haematol 1992;82:620.
8. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-9.
9. Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematol 1998;35(suppl 5):3-8.
10. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998;35(suppl 5):9-16.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
12. Levine LE, Bernstein JE, Soltani K, Medenica MM, Yung CW. Heparin-induced cutaneous necrosis unrelated to injection sites: a sign of potentially lethal complications. Arch Dermatol 1983;119:400-3.
13. Phillips JK, Majumdar G, Hunt BJ, Savidge GF. Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH). Br J Haematol 1993;84:349-50.
14. Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994;53:61-3.
15. Ulrick PJ, Manoharan A. Heparin-induced skin reaction. Med J Aust 1984;140:287-9.
16. Warkentin TE, Levine MN, Hirsch J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
17. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998;35(suppl 5):26-34.
18. Buller HR. Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost 2002;28(suppl 2):41-8.